株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

競合企業分析 - 癌免疫療法における抑制性・刺激性免疫調節薬:4レポートセット

4 Reports Bundle: Immuno-Oncology - Inhibitory and Stimulatory Immunomodulators

発行 La Merie Publishing 商品コード 408112
出版日 ページ情報 英文 455 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.80円で換算しております。
Back to Top
競合企業分析 - 癌免疫療法における抑制性・刺激性免疫調節薬:4レポートセット 4 Reports Bundle: Immuno-Oncology - Inhibitory and Stimulatory Immunomodulators
出版日: 2018年07月26日 ページ情報: 英文 455 Pages
担当者のコメント
癌の免疫療法における最新のパイプライン分析をまとめた、2018年度リリースされた4点の調査レポートをパッケージにした商品です。各阻害薬毎に、開発フェーズ、Mechanism of Action、Class of Compound、Indication、製品カテゴリ、特徴などまとめております。
概要

当レポートバンドルでは、制御性T細胞、腫瘍随伴マクロファージ (TAM)、骨髄由来免疫抑制細胞 (MDSC) を含む腫瘍微小環境における免疫抑制因子に対するT細胞、抗原提示細胞 (APC)/樹状細胞または腫瘍細胞の免疫刺激性チェックポイントについて、分析しています。

レポート1:PD-1およびPD-L1免疫チェックポイント阻害薬

  • プログラム細胞死1 (PD-1) 受容体拮抗薬
  • プログラム細胞死1受容体リガンド1 (PD-L1) 阻害薬
  • 企業のPD-1 & PD-L1免疫チェックポイント阻害薬R&Dパイプライン

レポート2:ネガティブ免疫チェックポイントCTLA-4, LAG-3, TIM-3 & その他の阻害薬

  • CTLA-4拮抗薬
  • LAG-3拮抗薬
  • TIM-3拮抗薬
  • その他のネガティブ免疫チェックポイントの阻害薬
  • 企業の免疫チェックポイント阻害薬R&Dパイプライン

レポート3:競合分析 - 免疫チェックポイントCD40, GITR, OX40, 4-1BB, CD27 & ICOSの活性化因子

  • 免疫チェックポイント活性化因子
  • 企業の免疫チェックポイント活性化因子R&Dパイプライン

レポート4:IDO, TGF-β/R, CXCR4, CSF-1R, CD47-SIRPアルファ, アデノシン, STING & その他による腫瘍微小環境モジュレーション

  • IDO & TDO阻害薬
  • TGF-ベータ/R阻害薬
  • CXCR4拮抗薬 & CXCL12阻害薬
  • CSF-1R拮抗薬 & CSF-1R tk阻害薬
  • CD47 - SIRPアルファ経路阻害
  • アデノシン経路
  • STING受容体刺激因子
  • その他の免疫抑制薬腫瘍微小環境の阻害薬
  • 企業の主要微小環境モジュレーターR&Dパイプライン
目次
Product Code: LMCA0160

This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).

Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:

  • Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018
  • Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018
  • Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018
  • Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment:

Negative Immune Checkpoints:

  • PD-1 (programmed cell death 1)
  • PD-L1 (programmed cell death ligand 1 (PD-L1)
  • CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
  • LAG-3 (Lymphocyte Activation Gene 3; CD223)
  • TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
  • TIGIT (T-cell Immunoreceptor with Ig and ITIM domains)
  • B7-H3 (CD276)
  • Others (VISTA: V-region Ig-containing Suppressor of T-cell Activation; BTLA: B- and T-Lymphocyte Attenuator; GARP: Glycoprotein A Repetitions Predominant; PVRIG; B7-H4)

Stimulatory Immune Checkpoints:

  • CD40 (TNFSFR5)
  • GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
  • OX40 (CD134; TNFSFR4)
  • 4-1BB (CD137; TNFSFR9)
  • CD27 (TNFSFR7)
  • ICOS (Inducible Co-Stimulator)

Immunosuppressive tumor microenvironment:

  • IDO (Indoleamine 2,3-dioxygenase
  • TDO (Tryptophan 2,3 dioxygenase)
  • TGF-β/R (Transforming Growth Factor beta/Receptor)
  • CXCR4 (Chemokine Receptor Type 4) & othe novel chemokines/receptors
  • CSF-1R (Colony Stimulating Factor-1 Receptor)
  • CD47 - SIRPα (Signal Regulatory Protein Alpha)
  • Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
  • STING (STimulator of INterferon Genes) Receptor
  • Others (e.g. arginase)

More than 190 unique molecules (many antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. This number has more than doubled since December 2016.

The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents

Report 1:

PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

1a) PD-1 Receptor Antagonists:

  • Approved and Marketed PD-1 Antagonists
  • Specific PD-1 Antagonists in Clinical Development for Regulated Markets
  • Bispecific PD-1 Antagonists in Clinical Development for Regulated Markets
  • Specific PD-1 Antagonists in Clinical Development for Less Regulated Markets
  • Specific PD-1 Antagonists in Non- or Pre-Clinical Development
  • Bispecific PD-1 Antagonists in Non- or Pre-Clinical Development

1b) PD-L1 Inhibitors:

  • Approved and Marketed PD-L1 Inhibitors
  • Specific PD-L1 Inhibitors in Clinical Development for Regulated Markets
  • Bispecific PD-L1 Inhibitors in Clinical Development for Regulated Markets
  • Specific PD-L1 Inhibitors in Clinical Development for Less Regulated Markets
  • Specific PD-L1 Inhibitors in Non- and Preclinical Development
  • Bi-and Multi-Specific PD-L1 Inhibitors in Non- and Preclinical Development

2) Corporate PD-1 and PD-L1 Checkpoint Inhibitor R&D Pipelines

Report 2:

CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018

1a) CTLA-4 Receptor Antagonists:

  • Selective CTLA-4 Antagonist in Clinical Development in Regulated Markets
  • Selective CTLA-4 Antagonist in Clinical Development in Less Regulated Markets
  • Bispecific CTLA-4 Antagonist in Clinical Development
  • Selective or Bispecific CTLA-4 Antagonists in Non-Clinical Development
  • Selective or Bispecific CTLA-4 Antagonist in Preclinical R&D

1b) LAG-3 Antagonists:

  • Relatlimab Pipeline
  • Selective LAG-3 Antagonists in Clinical Development
  • Bispecific LAG-3 Antagonists in Clinical Development
  • LAG-3 Antagonists in Non-Clinical Development
  • LAG-3 Antagonists in Preclinical R&D

1c) TIM-3 Antagonists:

  • Selective and Bispecific TIM-3 Antagonists in Clinical Development
  • Selective and Bispecific TIM-3 Antagonists in Non-Clinical Development
  • TIM-3 Antagonists in Preclinical R&D

1d) TIGIT Antagonists:

  • TIGIT Antagonists in Clinical Development
  • TIGIT Antagonists in Non-Clinical Development
  • TIGIT Antagonists in Preclinical R&D

1e) Other Inhibitors of Negative Immune Checkpoints

  • B7-H3 Targeted Immune Checkpoint Inhibitors
  • Inhibitors of Other Immune Checkpoints

2) Corporate Inhibitors of Negative Immune Checkpoints R&D Pipelines

Report 3:

CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators

  • CD40 Agonists
  • GITR Agonists
  • OX40 Agonists
  • 4-1BB (CD137) Agonists
  • CD27 Agonists1f) ICOS Agonists
  • Other Immune Checkpoint Activators

2) Corporate Immune Checkpoint Activator R&D Pipelines

Report 4:

Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

1a) IDO & TDO Inhibitors

  • First-Generation Selective IDO-1 Inhibitors
  • Novel Selective IDO-1 Inhibitors
  • Dual IDO/TDO Inhibitors
  • Selective TDO Inhibitors
  • Other Approaches for IDO or TDO Inhibition

1b) TGF-beta Inhibitors

  • Indirect TGF-beta Inhibition
  • Selective TGF-beta1 Inhibitors
  • Selective TGF-beta2 Inhibitors
  • Dual or Triple TGF-beta Inhibitors
  • Bispecific TGF-beta Inhibition

1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors

  • CXCR4 Antagonists
  • CXCL12 / SDF-1 Inhibitors

1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists

  • Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
  • Other Interleukin Inhibitors
  • CCR2/CCR5 Antagonists
  • CCR4 Antagonists

1e) CSF-1R Antagonists & CSF-1 Inhibitors

  • Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
  • Selective CSF-1R Antagonists and CSF-1 Inhibitors

1f) CD47 Antagonists & SIRPalpha Inhibitors

  • CD47 Antagonists
  • SIRPα Inhibitors
  • Bispecific CD47 Antagonists

1g) Adenosine Pathway Modulation

  • Selective Adenosine A2A Receptor Antagonists
  • Selective Adenosine A2B Receptor Antagonists
  • Dual Adenosine A2 Receptor Antagonists
  • CD73 Ectoenzyme Inhibitors
  • CD39 Ectoenzyme Inhibitors
  • Other Approaches

1h) STING Agonists

2) Corporate Tumor Microenvironment Modulator R&D Pipelines

Back to Top